Control of CNS disease with alectinib in patients previously
treated with crizotinib
Gadgeel, et al. ASCO 2016 (Abs. 9063)
MRI scans performed routinely at time of each tumour assessment (every 6 / 8 weeks)
0
0
6
12
18
Time (months)
3
9
15
0.7
0.5
0.3
0.2
0.1
0.6
0.4
CNS PD
Non-CNS PD
Death
Cumulative incidence
Patients with no baseline
CNS metastases (n=89)
Cumulative incidence of CNS-PD, non-CNS PD and death
INDICACIÓN NO APROBADA, EN INVESTIGACIÓN
